Maxor

Maxor announces the appointment of Kim Tzoumakas as new CEO and its strategic combination with ProxsysRx

Press Release – Jan 10, 2025 – Maxor National Pharmacy Services, LLC PLANO, Texas, Jan. 10, 2025 /PRNewswire/ — Maxor National Pharmacy Services (“Maxor”), a leading pharmacy care solutions company, announced today that Kim Tzoumakas has been named the Company’s new Chief Executive Officer and has also been appointed to the Board of Directors, effective January 6, 2025. Ms. Tzoumakas succeeds Mike Ellis, who has retired as CEO and moved … Continue reading Maxor announces the appointment of Kim Tzoumakas as new CEO and its strategic combination with ProxsysRx

NeoGenomics Laboratories

NeoGenomics Announces Chief Executive Officer Succession

Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO Company reaffirms Fiscal 2024 financial guidance Press Release – January 10, 2025 – FT. MYERS, Fla. – NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, … Continue reading NeoGenomics Announces Chief Executive Officer Succession

hovione

Hovione strengthens its global position as a top employer for the third consecutive year

Hovione has once again solidified its position as a top employer. Press Release – Jan 16, 2025 Lisbon, January 16, 2025 – Hovione, an international integrated pharmaceutical development and manufacturing organization, has once again solidified its position as a top employer. For the third consecutive year, all four of its manufacturing sites – Lisbon (Portugal), Cork (Ireland), East Windsor (NJ, USA), and Macau – have been … Continue reading Hovione strengthens its global position as a top employer for the third consecutive year

JOHNSON & JOHNSON

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson’s robust lineup of … Continue reading Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Hippocratic AI

Hippocratic AI Launches AI Agent App Store for Healthcare

Empowering Clinicians to Extend Their Impact and Earn Through Innovation Press Release – January 09, 2025 – PALO ALTO, Calif. – Hippocratic AI, the company that pioneered the first healthcare LLM for patient-facing non-diagnostic clinical tasks, today announced the launch of its Healthcare AI Agent App Store.Marking a bold step forward in healthcare innovation, the AI Agent App Store empowers clinicians to design and shape artificial … Continue reading Hippocratic AI Launches AI Agent App Store for Healthcare